A pilot study on treatment of infantile cystinosis with mesenchymal stem cells

Main Article Content

Faysal Gok*
Cengiz Zeybek
Ayse Balat
Olcay Y Jones

Abstract

Infantile cystinosis is a lysosomal storage disease leading to end stage kidney disease at early ages. There is no effective treatment and patients require long term dialysis or kidney transplant for survival. We present our experience on three affected children who received HLA matched allogeneic stem cell transplant. The protocol used was novel and designed to promote engraftment. The primary endpoint was safety for treatment related mortality or morbidity; All three children survived without serious adverse effects during extended follow up for over 4 years. Although we could not prove engraftment, all three children met secondary end point of sustained target functions over a 6 month follow-up. Further studies are warranted to further evaluate safety and efficacy of MSC treatment for infantile cystinosis.

Article Details

Gok, F., Zeybek, C., Balat, A., & Jones, O. Y. (2019). A pilot study on treatment of infantile cystinosis with mesenchymal stem cells. Journal of Clinical Nephrology, 3(3), 181–185. https://doi.org/10.29328/journal.jcn.1001046
Research Articles

Copyright (c) 2019 Gok F, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ruivo R. Anne C, Sagne C, Gasnier B. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochem Biophys Acta. 2009; 1793: 636–649. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19146888

Sansanwal P, Sarwal MM. Abnormal mitochondrial autophagy in nephropathic cystinosis. Autophagy. 2010; 6: 971-973. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20729635

Anikster Y, Shotelersuk V, Gahl WA. CTNS mutations in patients with cystinosis. Hum Mutat. 1999; 14: 454–458. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10571941

Attard M, Jean G, Forestier L, Cherqui S, van't Hoff W, et al. Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet. 1999; 8: 2507–2514. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10556299

Gahl WA, Thoene JG, Schneider JA. Cystinosis. New Engl J Med. 2002; 347: 111–121. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12110740

Goldman H, Scriver CR, Aaron K, Delvin E, Canlas Z. Adolescent cystinosis: comparisons with infantile and adult forms. Pediatrics. 1971; 47: 979–988. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/5141767

Cogan DG, Kuwabara T, Kinoshita J, Sheehan L, Merola L. Cystinosis in an adult. J Am Med Assoc. 1957; 164: 394–396. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/13415995

Brodin-Sartorius A, Tete MJ, Niaudet P, Antignac C, Guest G, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012; 81: 179–189. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21900880

Rocca CJ, Cherqui S. Potential use of stem cells as a therapy for cystinosis. Pediatr Nephrol. 2019; 34: 965-973. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29789935

Cahill RA, Jones OY, Klemperer M, Steele A, Mueller TO, et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol Blood Marrow Transplant. 2004; 10: 709-717. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15389437

Syres K, Harrison F, Tadlock M, Jester JV, Simpson J, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood. 2009; 114: 2542–2552. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19506297

Iglesias DM, El-Kares R, Taranta A, Bellomo F, Emma F, et al. Stem Cell Microvesicles Transfer Cystinosin to Human Cystinotic Cells and Reduce Cy stine Accumulation In vitro. PLoS One. 2012; 7: e42840. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22912749